Slide 1: Optiscan Imaging Ltd
Optiscan Imaging Ltd (ASX:OIL) Enabling “Real-time Virtual Biopsy” for Human Cancer Screening and Surgical Margin Detection
Slide 2: Notice
Notice This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) as at 11 June 2019. The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain all of the information which a prospective investor may r
Slide 3: Notice
Notice Not an offer or financial product advice This presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This presentation does not satisfy the disclosure requirements for a disclosure doc
Slide 4: Corporate Snapshot
Corporate Snapshot Board Major Shareholders Darren Lurie – Executive Chairman ▪ Peters Investments Pty Ltd: 10.0% B.LLB (Hons) and B.COM (Hons) ▪ Ibsen Pty Ltd: 9.9% Former Group CFO and Head of Corporate Development for EduCo International (an investee company of Baring Private Equity Asia). Darren
Slide 5: From Laboratory Benchtop to Operating Theatre
From Laboratory Benchtop to Operating Theatre Desktop Confocal Microscope Optiscan’s confocal device Successfully miniaturised high resolution benchtop confocal microscope into hand-held probe with 4.0mm diameter providing unique microscopic imaging for clinicians. Underpinned by multi-patented tech
Slide 6: Commercial Focus
Commercial Focus ▪ Optiscan entering new commercial phase ▪ Sales of Carl Zeiss Meditec CONVIVO are expected in the first few months of FY20 ▪ Optiscan is implementing plans to seek regulatory approvals for the sale of its own in human clinical device in multiple cancer applications ▪ FIVE2 (ViewnVi
Slide 7: Optiscan Technology Enables “Real Time Virtual Biopsy”
Optiscan Technology Enables “Real Time Virtual Biopsy” Optiscan technology changing pathology and surgical cancer practice Screening, early cancer Tumour margin detection diagnosis and targeted in cancer surgery biopsies Images available instantaneously compared to waiting 3-4 days for the return of
Slide 8: Cancer Cases Worldwide – Addressable Market
Cancer Cases Worldwide – Addressable Market 18.1M total 297,000 350,000 570,000 2.1M Breast 3.4M Upper and Brain and Lip and Cervix& cancer cases CNS cancer Oral cancer Uterus cancer cancer cases Lower GI cancer cases p.a. cases p.a. cases p.a. p.a. p.a. cases p.a. Carl Zeiss Application with Optisc
Slide 9: Current Cancer Applications
Current Cancer Applications CANCER PROGRESS APPLICATIONS Brain Cancer • Carl Zeiss Meditec Collaboration – FDA and CE Mark already obtained • Expected sales in first few months of FY20 Oral and Cervical • Optiscan seeking FDA and other regulatory approvals for own device* Cancer • Expect Carl Zeiss
Slide 10: Brain Cancer – Collaboration with Carl Zeiss Meditec AG
Brain Cancer – Collaboration with Carl Zeiss Meditec AG ▪ United States (FDA 510(k)) and European (CE Mark) approvals obtained ▪ CONVIVO “Digital Biopsy Tool” (Check) an integral part of the 3 step Zeiss Tumour Workflow in Neurosurgery ▪ Sales expected in first few months of FY20 ▪ https://www.zeiss
Slide 11: Optiscan is Seeking:
Optiscan is Seeking: ❑ 510(k) clearance (USA) ❑ CE Mark (Europe) ❑ TGA approval (Australia) Applications with Optiscan’s Existing Probe Design For use of the Optiscan FDA and other regulatory approvals will significantly broaden clinical device in human the clinical applications for the sale of Opti
Slide 12: Breast Cancer - The Most Common Cancer in Women
Breast Cancer - The Most Common Cancer in Women 2.1 15% 556 145 Million of cases centers hospitals 2.1 million new cases of 15% of all new cancer There are 556 Breast There are 145 hospitals breast cancer predicted cases in the United Centers in the USA in Australia performing in 2018 (globally)1 St
Slide 13: Breast Cancer Clinical Trial
Breast Cancer Clinical Trial Trial at Hollywood Private Hospital in Perth with Principal Investigators ▪ Dr Peter Willsher, Breast Surgeon of the Breast Cancer Research Centre –WA ▪ Dr Jespal Gill, Anatomical Pathologist and Head of Histopathology of Western Diagnostic Pathology ▪ Dr Philip Currie –
Slide 14: Oral, Cervical and Oesophageal Cancer Applications: Working with MSK
Oral, Cervical and Oesophageal Cancer Applications: Working with Memorial Sloan Kettering Cancer Centre (MSK) ▪ MSK is the world’s oldest and largest private cancer center, situated in New York, USA. ▪ MSK’s use of Optiscan’s device provides critical endorsement of its unique imaging capabilities. ▪
Slide 15: Gastrointestinal Applications
Gastrointestinal Applications ▪ 3.4 Million Gastrointestinal cancer cases world wide ▪ MSK collaboration for oesophageal (upper GI) application ▪ Previous successful collaboration with Pentax Medical with over 100 devices sold ▪ Collaboration ceased following takeover of Pentax Medical ▪ Pentax syst
Slide 16: Optiscan Technology in Pre-clinical Market
Optiscan Technology in Pre-clinical Market Progress in the Preclinical market Research Applications with FIVE2 (ViewnVivo) ▪ Product re-branded FIVE2 (ViewnVivo) ▪ Cancer research ▪ Identified opportunities to change ▪ Tissue regeneration existing research techniques for ▪ Cell tracking enhanced out
Slide 17: Key Milestones for the Coming Financial Year
Key Milestones for the Coming Financial Year July 2019 December 2019 June 2020 1st Half Full Year 1 Lodge submissions for FDA and other regulatory 5 MSK commence cervical and oesophageal cancer approvals for one or more cancer applications trials 2 Enter production phase for supply of devices to 6 E
Slide 18: Investment Highlights
Investment Highlights • Optiscan is entering into new commercial phase • Optiscan device enabling “Real-time Virtual Biopsy” for Human Cancer Screening and Surgical Margin Detection • Collaboration with Carl Zeiss Meditech AG for Brain Cancer Surgical Device (US FDA and EU certifications already app